RECURRENT GLIOMA

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…

This phase 2 trial is testing the drug larotrectinib in children and young adults (ages 1 to 21) with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have a specific genetic change called an NTRK fusion. The cancers have either come back after treatment…

This early-phase trial tests a new immune cell therapy for people with recurrent or treatment-resistant malignant glioma, a type of brain cancer. The treatment uses the patient's own T cells, modified in the lab to recognize and attack cancer cells. The main goal is to find the s…

This study is testing a new type of MRI scan that looks at sodium and other chemicals in the brain to get a clearer picture of brain tumors (gliomas). The goal is to improve how doctors detect, diagnose, and track these tumors. The study includes healthy volunteers and people wit…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study screens children and teens with advanced solid tumors, lymphomas, or histiocytic disorders to find genetic changes in their cancer cells. Participants undergo biopsies and scans to identify mutations that can be targeted by specific drugs. The goal is to see if matchin…

This pilot study aimed to see if a diet low in two specific nutrients (cysteine and methionine) could affect metabolism in patients with recurrent gliomas. Up to 30 participants were to be randomly assigned to either a normal diet or the special diet for 2, 4, or 7 days before st…

This early-stage trial enrolls 16 adults with recurrent IDH-mutant gliomas who are scheduled for surgery. Participants take niraparib for one month before their operation so researchers can measure how much drug reaches the tumor and how it affects cancer cells. The goal is to ga…